(CEL) |
| 0 (0%) 04-16 06:26 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 326.05 |
| Resistance 1: | 279.15 |
| Pivot price: | 268.25 |
| Support 1: | 262.78 |
| Support 2: | 252.66 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 7.290 |
| Book Value | 23.460 |
| PEG Ratio | 0.00 |
| Gross Profit | 25.352 |
| Profit Margin (%) | 12.91 |
| Operating Margin (%) | 14.71 |
| Return on Assets (ttm) | 7.8 |
| Return on Equity (ttm) | 22.5 |
Company news
Thu, 16 Apr 2026
CEL (TSE:5078) Margin Compression Reinforces Bearish Earnings Narratives - simplywall.st
Tue, 14 Apr 2026
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - Business Wire
Tue, 14 Apr 2026
Cema-Cel Improves MRD Clearance as First-Line Consolidation in Large B-Cell Lymphoma - OncLive
Mon, 13 Apr 2026
Allogene's off-the-shelf CAR-T strikes at residual lymphoma cells in Phase II win - FirstWord Pharma
Mon, 13 Apr 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength Of Cellectis’ Allogeneic Car-T Platform - TradingView — Track All Markets
Mon, 13 Apr 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
